Quantcast
Scientists Develop First Cancer Immunotherapy For Dogs

Scientists Develop First Cancer Immunotherapy For Dogs

University of Veterinary Medicine Vienna Nearly every second dog develops cancer from the age of ten years onward. A few therapies derived from human medicine are available for dogs. A very successful form of therapy by which antibodies...

Latest Management of cancer Stories

2014-07-02 16:24:28

In this phase two study, 50 percent of glioblastoma patients lived for two years, an encouraging result for one of the most deadly cancers that often kills patients within one year of diagnosis CHICAGO, July 2, 2014 /PRNewswire-USNewswire/ -- Patients newly diagnosed with glioblastoma multiforme (GBM) and treated with an experimental cancer vaccine made from the patient's own tumor in addition to standard of care lived longer compared to those who received standard of care alone,...

2014-07-01 10:07:43

University of Pennsylvania School of Medicine Lack of clinical trial data, guidelines on HIV patients with cancer may contribute to health disparity HIV-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a new, large retrospective study from researchers in Penn Medicine's Abramson Cancer Center and the National Cancer Institute (NCI) published online ahead of print in the Journal...

2014-06-27 12:26:33

Study published in Clinical Cancer Research and co-led by Adaptive Biotechnologies and the University of Washington demonstrates clinical utility of Next Generation Immune Profiling SEATTLE, June 27, 2014 /PRNewswire/ -- Adaptive Biotechnologies today announced results demonstrating enhanced accuracy and sensitivity of clonoSEQ in identifying risk of relapse in patients with B-cell Acute Lymphoblastic Leukemia (B-ALL), a childhood leukemia, compared to flow cytometry, the current...

2014-06-24 23:03:05

New research report “Cancer Cell Therapy Market & Pipeline Insight” elaborated by Kuick Research is now available at MarketPublishers.com London, UK (PRWEB) June 24, 2014 Over the past 5 years, the world cancer cell therapy market witnessed strong growth. Furthermore, this market is expected to keep on following an upward trend in the years ahead, driven by the increasing cancer incidence worldwide, rising adoption of novel drugs, high unmet needs along with the continuously...

2014-06-24 08:31:08

U.S. Phase 2a Clinical Trial in Recurrent Glioblastoma to Initiate in Early 2015 SYDNEY, June 24, 2014 /PRNewswire/ -- EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV(TM) nanocells packaged with doxorubicin for the treatment...

2014-06-24 08:30:24

Using CyberKnife and chemotherapy, doctors treat primary and metastatic tumors FENTON, Mo., June 24, 2014 /PRNewswire/ -- When St. Louis CyberKnife patient Theresa Thompson was diagnosed with stage IV lung cancer, doctors determined the disease had spread beyond her lungs to her brain. http://photos.prnewswire.com/prnvar/20140623/120686 While stage IV lung cancer is difficult to treat, doctors reviewed her case and decided to aggressively treat with CyberKnife and chemotherapy....

2014-06-24 08:29:35

Yet Canadians in the dark about cancer survival rates OTTAWA, June 24, 2014 /CNW/ - Cancer isn't always a matter of life and death anymore - today, an increasing number of Canadians are living with cancer as a chronic condition. However, the majority of Canadians and the healthcare system have not necessarily responded to this shift. "The fact is, 63 per cent of Canadian cancer patients live longer than five years after diagnosis(i), and if a cancer patient survives past one year,...

2014-06-18 04:21:16

Unique Immuno-Oncolytic Therapy Gets Closer to a More Effective, Safer Cancer Treatment and Potential Cure CLEVELAND, June 18, 2014 /PRNewswire-USNewswire/ --­­ Western Oncolytics Ltd., a biotech company specializing in immuno-oncolytic cancer therapies, has closed $275,000 in seed funding. The proceeds are planned to set a path toward clinical trials and execute initial manufacturing for its novel virus-based cancer therapy, which delivers genes to guide the immune system to kill...

2014-06-17 08:29:05

Side-By-Side Genomic Analysis of Patients' Tumor and TumorGraft Mouse Avatars Before and After Treatment Also to be Conducted NEW YORK and HACKENSACK, N.J., June 17, 2014 /PRNewswire/ -- Icahn School of Medicine at Mount Sinai and Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the initiation of a clinical trial evaluating the use of Champions...

2014-06-16 08:28:29

Company continues to engage leading cancer treatment centers to investigate non-invasive methods of cancer mutation detection in order to advance patient care SAN DIEGO, June 16, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related